With TriMed® Radiofrequency Ablation (RFA), patients with early breast cancer has the decisive advantage that it replaces surgery and makes hospital stay unnecessary. Instead, the tumor is denaturated through a unique heating technique that works different from current RFA technique. The TriMed® method is simple, painless, fast and cost efficient.
Since the procedure is less invasive than surgery the recovery time is much shorter. This also means less use of resources. RFA basically means inserting an electrode into the tumor, heating up the tumor volume and a surrounding safety zone by allowing high frequency current to pass through it in order to completely kill the cancer cells.
Until now conventional RFA has been subject to several drawbacks. These difficulties have prevented the method to be a preferred therapy especially in breast cancer. For example achieving good control of the current density and temperature could be difficult, which leads to carbonization at the interface between the electrode and the tumor tissue. Furthermore there is a difficulty to place and evaluate with precision the location of the electrode, especially in hard calcified and fibrous tumors, which typically are elastically attached to the surrounding tissues.
There is also a high risk of dissemination of cancer cells, so called seeding, when the electrode is inserted in the tumor tissue.
Minimally-invasive treatment of early stage breast cancer: a feasibility study using radiofrequency ablation under local anesthesia. Schässburger KU, Löfgren L, Lagerstedt U, Leifland K, Thorneman K, Sandstedt B, Auer G, Wiksell H. Breast. 2M014 Apr;23(2):152-8. doi: 10.1016/j.breast.2013.12.007. Epub 2014 Jan 1. PubMed PMID: 24388735.
Radiofrequency Ablation of Breast Cancer: A Retrospective Study. Toshikazu Ito et al. Clinical Breast Cancer, 25 September 2017.
TriMed® 500 is packaging all the functonality of the TriMed® method into one easy to operate unit.
It is expected that TriMed® will be an attractive tool regarding palliative treatment of cancer tumors.
Today regular RFA is acknowledged to be an effective treatment in a subset of patients and has a potential to save them from symptoms of the tumors when conventional palliative treatments such as surgery, radiotherapy and chemotherapy are difficult. Since most palliative patients are not fully curable, considerations of the effect of the treatment must be balanced against the strain of the procedure.
Here will TriMed® be advantageous to surgical treatments. The time to market for palliative use will be shorter due to shorter clinical studies that will be focused on safety and direct effect of therapy rather than the long-time outcome. Palliative use will initially be an early contribution to the revenue.